← Back to Search

Convulsive Therapy

Convulsive Therapies for Depression (CORRECT-C Trial)

N/A
Recruiting
Led By Daniel Blumberger, MD, MSc
Research Sponsored by Centre for Addiction and Mental Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
achieve remission defined as HRSD-24 < 10 and a > 60% decrease in scores from baseline on two consecutive ratings OR achieve response on HRSD-24 defined as a 50% reduction in symptoms from baseline
are inpatients or outpatients
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights

CORRECT-C Trial Summary

This trial is comparing three different types of electrical shock therapy to see which one is most effective in treating depression.

Who is the study for?
This trial is for adults who've been diagnosed with depression or bipolar disorder and have responded to initial bitemporal ECT treatment. They must be able to consent, maintain current antidepressant use, adhere to the schedule, meet safety criteria for MST, and not be pregnant. Exclusions include dementia, metal implants in the head, significant sensory impairments or unstable medical conditions.Check my eligibility
What is being tested?
The study compares Magnetic Seizure Therapy (MST) with two types of electroconvulsive therapy (ECT): Bitemporal ECT and RUL-UB ECT. It aims to determine which method best maintains response in patients during continuation treatment after an acute phase of depression or bipolar disorder.See study design
What are the potential side effects?
Potential side effects may include memory issues, confusion immediately after treatments, physical side effects like muscle aches or headaches from convulsions induced by therapies. Each individual's experience can vary.

CORRECT-C Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My depression symptoms have significantly improved.
Select...
I am currently receiving medical care, either staying in the hospital or visiting as an outpatient.
Select...
I am 18 years old or older.
Select...
I agree to not change my current antidepressant treatment during the study.
Select...
I am currently receiving medical care, either staying in the hospital or visiting as an outpatient.
Select...
I am willing and able to agree to treatment and research as per my psychiatrist's advice.
Select...
I am willing and able to agree to treatment and research as confirmed by my psychiatrist.
Select...
I am deemed suitable for convulsive therapy by a psychiatrist and an anesthesiologist.
Select...
I am 18 years old or older.

CORRECT-C Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Cognitive adverse effects as indexed by the Autobiographical Memory Test (AMT)
Difference in HRSD-24 Scores between MST and RUL-UB at 6 months
Secondary outcome measures
Differences in HRSD-24 scores between MST, RUL-UB ECT and bitemporal ECT
Electroconvulsive Therapy

CORRECT-C Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: Magnetic Seizure Therapy (MST)Experimental Treatment1 Intervention
MST treatments will be administered using the MagPro MST with Cool TwinCoil.
Group II: RUL-UB ECTActive Control1 Intervention
ECT treatments will be administered using the MECTA spECTrum 5000Q or MECTA Sigma
Group III: Bitemporal ECTActive Control1 Intervention
ECT treatments will be administered using the MECTA spECTrum 5000Q or MECTA Sigma

Find a Location

Who is running the clinical trial?

Brain CanadaOTHER
17 Previous Clinical Trials
5,799 Total Patients Enrolled
Centre for Addiction and Mental HealthLead Sponsor
351 Previous Clinical Trials
80,651 Total Patients Enrolled
University of British ColumbiaOTHER
1,410 Previous Clinical Trials
1,766,444 Total Patients Enrolled

Media Library

Bitemporal ECT (Convulsive Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT03711019 — N/A
Major Depressive Disorder Research Study Groups: Magnetic Seizure Therapy (MST), RUL-UB ECT, Bitemporal ECT
Major Depressive Disorder Clinical Trial 2023: Bitemporal ECT Highlights & Side Effects. Trial Name: NCT03711019 — N/A
Bitemporal ECT (Convulsive Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03711019 — N/A
Major Depressive Disorder Patient Testimony for trial: Trial Name: NCT03711019 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are participants being enrolled in this trial at the present time?

"Affirmative. The information hosted on clinicaltrials.gov suggests that this experiment is actively recruiting participants with 165 subjects needed from 3 medical centres. This trial was first posted on the 22nd of October 2018 and has since been updated as recently as 16th November 2021."

Answered by AI

How many participants are being selected for this research trial?

"Affirmative. Clinicaltrials.gov highlights that this clinical trial is currently recruiting participants; the initial posting was on October 22nd 2018, with a most recent update taking place November 16th 2021. 165 patients need to be recruited from 3 distinct medical centres."

Answered by AI

Who else is applying?

What state do they live in?
California
What site did they apply to?
UBC Hospital, University of British Columbia (UBC)
What portion of applicants met pre-screening criteria?
Met criteria
How many prior treatments have patients received?
0

Why did patients apply to this trial?

I am so tired of wasting my life with this illness. It has robed me of this precious time I have and I want to live again.
PatientReceived no prior treatments
~26 spots leftby Mar 2025